CJC-1295 vs Tesamorelin: Head-to-Head Comparison
CJC-1295 and tesamorelin are both GHRH analogs but tesamorelin is the only one that is FDA-approved (for HIV-associated lipodystrophy). Tesamorelin has robust clinical trial data showing visceral fat reduction, while CJC-1295 offers convenience with its extended half-life.
Side-by-Side Comparison
| Dimension | CJC-1295 | Tesamorelin |
|---|---|---|
| Evidence Level | Phase II trials | Phase III trials, FDA-approved |
| FDA Status | Not approved | FDA-approved (Egrifta) for HIV lipodystrophy |
| Mechanism | Modified GHRH with DAC for extended action | GHRH analog (trans-3-hexenoic acid modification) |
| Primary Use | GH optimization, anti-aging, body composition | Visceral fat reduction in HIV lipodystrophy |
| Half-Life | ~6-8 days (DAC) | ~26-38 minutes |
| Side Effects | Injection site reactions, water retention | Injection site reactions, arthralgia, peripheral edema |
| Cost | Moderate (research peptide pricing) | Very high (branded pharmaceutical) |
Peptide Overviews
CJC-1295
BHuman StudiesCJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Available in two forms: with and without Drug Affinity Complex (DAC), which extends its half-life.
Tesamorelin
AFDA ApprovedTesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
CJC-1295 vs Tesamorelin: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.